Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

Dana-Farber Cancer Institute

P. Richardson

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

A New Consensus for Classification of High-Risk Myeloma Based on Cyt…

Jill Corre

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Management of AL Amyloidosis

GRACE

S. Rajeeve

Experts Discuss the Management of Monoclonal Gammopathy of Renal Sig…

MyCancerHaven

R. Vij, N. Leung

POEMS Syndrome Management

MyCancerHaven

R. Vij, D. Dingli

AI in Multiple Myeloma: Recent Findings and Opportunities

Winship Cancer Institute - Emory University

A. Madabhushi

Multiple Myeloma: Initial Treatment Approaches

University of Colorado Division of Hematology

A. Hirose

Whole-Body MRI: Past, Present, and Future

Houston Methodist

N. Gupta

CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Direc…

Rush University Medical Center

A. Suvannasankha

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

Treating Amyloidosis in 2024

MyCancerHaven

R. Vij, J. Zonder

Diagnosing AL Amyloidosis

GRACE

S. Rajeeve

Frontline Treatment Strategies in MM: A Comprehensive Overview of Cl…

Yale Cancer Center

T. Parker

"You Have AL-Amyloidosis": Counseling Newly Diagnosed Patients

Morie Gertz

Multiple Myeloma: Disease Origins and Pathophysiology

University of Colorado Division of Hematology

A. Hirose